Redefining Reference Standards

What is the impact of molecular assay failure in your laboratory?
Identify and eliminate variability in your laboratory today

Publication: Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations.

07/01/2014

Horizon Diagnostics Reference Standards used in Ion Torrent AmpliSeq™ Cancer Hotspot Panel:

Abstract Background: Somatic mutation analysis is standard of practice for solid tumors in order to identify therapeutic sensitizing and resistance mutations. Our laboratory routinely performed standalone PCR-based methods for mutations in several genes. Rapid discovery and introduction of new therapeutics has demanded additional genomic information for adequate management of the cancer patient. We evaluated a next generation sequencing assay, the Ion Torrent AmpliSeq Cancer Hotspot Panelv2 (CHPv2), capable of identifying multiple somatic mutations in 50 genes in a single assay. Methods: Accuracy, precision, limit of detection, and specificity were evaluated using DNA from well-characterized cell lines, genetically engineered cell lines fixed and embedded in paraffin, and previously tested mutation positive or negative, formalin-fixed, paraffin-embedded (FFPE) tissues. Normal kidney, tonsil and colon FFPE tissues were used as controls. Results: Accuracy studies showed 100% concordance in each patient sample between previous PCR results and the corresponding variants identified using the Ion Torrent panel. Precision studies gave consistent results when libraries were prepared from the same original DNA and were run on multiple 316 chips. The limit of detection was determined to be 5% for single nucleotide variants (SNVs) and 20% for insertions and deletions (indels). Specificity studies using normal FFPE tissue previously tested by PCR methods were also 100%. Conclusions: We have evaluated the performance of the AmpliSeq Cancer Panel Hotspotv2 and show that it is suitable for clinical testing. This next generation sequencing panel has allowed the laboratory to consolidate a broader range of molecular oncology testing to a single platform and single assay.

To Read More Click Here


Media contact

Katie Odgaard, Zyme Communications Ltd.
Tel: +44 (0) 7787 502 947   Email: katie.odgaard@zymecommunications.com

Choose Year
2011 | 2012 | 2013 | 2014 | 2015

Paragraph explaining benefits of Biocair

×

Login Error


There was an error with your login - please try again.

Forgotten your password? Click here

OK ×

Recover your password

Please enter your email address and we'll send you a reset link

×

Thank you.


We've sent you an email to reset your password.

OK ×

Add Voucher


Sorry, Unable to add voucher

OK ×

Account Error


There was an error updating your details.

OK ×

Thank you.


Your changes have been saved.

OK ×

Thank you


Thank you for registering to the Horizon DX website. We hope you enjoy and benefit from our online resources, and please feel free to contact us if you have any queries or feedback through the website itself or at info@horizondx.com.


×

Thank you.


Items have been saved to your basket.

OK ×